CESTAT Chennai Upholds Customs Duty Exemption for ELFA Diagnostic Kits

Aadrikaa Legal Services (ALS) – IDT Tax I Arbitration I Litigation

Date: 30.06.2026

CESTAT Chennai Upholds Customs Duty Exemption for ELFA Diagnostic Kits

The Customs, Excise & Service Tax Appellate Tribunal (CESTAT) Chennai recently delivered a significant judgment in the case of M/s. Biomerieux India Private Limited, addressing the classification and exemption eligibility of imported diagnostic test kits under Indian customs law. This article provides a detailed overview of the dispute, the arguments from both sides, and the Tribunal’s reasoning and final decision.

Background of the Case

Biomerieux India imported various diagnostic test kits, including ‘VIDAS TSH 60 TESTS’ and ‘VIDAS T3 60 TESTS’, declaring them as ‘VIDAS Test Kits’ under Customs Tariff Item 38221990. The company claimed a concessional Basic Customs Duty (BCD) rate of 5% by availing exemption under Notification No. 50/2017-Cus., specifically for Enzyme-Linked Immunosorbent Assay (ELISA) kits. The kits were also assessed at a concessional IGST rate under Notification No. 01/2017-Integrated Tax (Rate).

The Dispute: ELISA vs. ELFA Kits

The core issue arose when customs authorities, based on intelligence and investigation, alleged that the imported kits were not ELISA kits but Enzyme-Linked Fluorescent Assay (ELFA) kits. The Department argued that ELFA kits are technologically distinct from ELISA kits and thus not eligible for the same exemption. This led to seizure of goods, demand for differential duty (over Rs. 68 crore), and imposition of penalties and confiscation proceedings.

Key Arguments

Biomerieux India (Appellant)

1. Scientific Principle: Argued that ELFA is a technologically advanced variant of ELISA, differing only in the detection method (fluorescence vs. color change), but fundamentally based on the same immunoassay principle.
2. Technical Literature: Cited authoritative sources (e.g., The Immunoassay Handbook by David Wild) confirming that ELISA encompasses chromogenic, chemifluorescent, and chemiluminescent detection methods.
3. Expert Clarifications: Relied on clarifications from the National Institute of Biologicals (NIB) and Central Drugs Standard Control Organization (CDSCO), which stated that ELFA and ELISA are essentially the same for regulatory purposes.
4. Precedent and Consistency: Pointed to earlier customs decisions granting exemption to ELFA kits and emphasized the need for uniformity in tax treatment.

Customs Department (Respondent)

1. Distinct Technologies: Maintained that ELFA and ELISA are different due to their detection mechanisms and performance characteristics (e.g., sensitivity, speed).
2. Strict Interpretation: Cited Supreme Court judgments requiring strict interpretation of exemption notifications, arguing that only goods explicitly described (ELISA kits) are eligible.
3. Alleged Misdeclaration: Claimed that Biomerieux knowingly misdeclared ELFA kits as ELISA kits to avail the exemption.

Tribunal’s Analysis and Findings

1. Scientific Basis: The Tribunal found that ELFA is not a separate scientific principle but an advanced application within the ELISA framework. Both operate on the same antigen-antibody interaction principle, differing only in the detection signal (fluorescence vs. color).
2. Technical Evidence: Accepted technical literature and expert clarifications confirming that ELISA methods include fluorescence-based detection.
3. Legal Interpretation: Emphasized that exemption entries for scientific and medical products should not be interpreted rigidly, ignoring technological advancements. Cited Supreme Court precedents supporting purposive interpretation in line with evolving technology.
4. Consistency and Expert Opinion: Noted that customs authorities had previously accepted ELFA kits as eligible for exemption based on expert regulatory opinions, and such consistency is vital for certainty in tax administration.
5. No Willful Misstatement: Held that the dispute was interpretational, not a case of deliberate misdeclaration or fraud, and thus the extended limitation period and penalties were not justified.

Final Order

The Tribunal set aside the order denying exemption, quashed the demand for differential duty, interest, confiscation, and penalties, and allowed the appeal in favor of Biomerieux India.

Implications of the Ruling

• Technological Evolution Recognized: The decision affirms that exemption benefits for diagnostic kits should keep pace with scientific advancements, ensuring access to modern healthcare technologies.
• Importance of Expert Opinion: Regulatory clarifications from bodies like CDSCO and NIB play a crucial role in resolving technical disputes.
• Certainty in Tax Administration: The ruling underscores the need for uniformity and consistency in customs assessments across jurisdictions.

Conclusion

The CESTAT Chennai’s judgment in the Biomerieux case sets an important precedent for the classification and exemption of advanced diagnostic kits under Indian customs law. It highlights the necessity of interpreting tax exemptions in light of scientific progress and regulatory expertise, ultimately supporting the broader goal of affordable and advanced healthcare in India.

Connected Matter

Supreme Court Clarifies Excise Duty Exemption for Brass Circles

Source: CESTAT Chennai

Disclaimer

Handy Download:

Write to us at office@aadrikaalaw.com

Tel: +91-11-4999 2707 I +91-9999005379

www.aadrikaalaw.com